Transcend Capital Advisors LLC Sells 3,364 Shares of Thermo Fisher Scientific Inc. $TMO

Transcend Capital Advisors LLC reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 60.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,212 shares of the medical research company’s stock after selling 3,364 shares during the quarter. Transcend Capital Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,281,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. JPL Wealth Management LLC bought a new stake in Thermo Fisher Scientific in the third quarter worth approximately $28,000. Highline Wealth Partners LLC increased its holdings in Thermo Fisher Scientific by 126.9% in the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock worth $29,000 after purchasing an additional 33 shares in the last quarter. Beacon Financial Strategies CORP bought a new stake in Thermo Fisher Scientific in the fourth quarter worth approximately $29,000. Olistico Wealth LLC bought a new stake in Thermo Fisher Scientific in the fourth quarter worth approximately $29,000. Finally, Cloud Capital Management LLC bought a new stake in Thermo Fisher Scientific in the third quarter worth approximately $31,000. 89.23% of the stock is currently owned by institutional investors.

Trending Headlines about Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Zacks and Yahoo analyses highlight Thermo Fisher as one of a small group of medical stocks likely to beat upcoming quarterly earnings (strong earnings-surprise history and favorable Earnings ESP), which can drive upside on an earnings beat. These 2 Medical Stocks Could Beat Earnings
• Positive Sentiment: Thermo Fisher’s PPD clinical research unit announced a strategic collaboration with HealthVerity to expand real‑world data capabilities — a revenue-accretive move that strengthens its clinical services offering and makes future contract wins more likely. Thermo Fisher PPD Clinical Research Collaborates with HealthVerity
• Positive Sentiment: Industry reports project strong growth in allergy diagnostics and small‑molecule CDMO markets through 2030–2033 and list Thermo Fisher as a leading participant — reinforcing a favorable long‑term demand outlook for its diagnostics and CDMO businesses. Allergy Diagnostic Market Forecast Small Molecule Innovator API CDMO Market Outlook
• Neutral Sentiment: Barclays cut its TMO price target from $650 to $625 but maintained an “Overweight” rating — a mild trimming of upside expectation but still institutional support for the stock. Barclays Lowers Price Target to $625
• Neutral Sentiment: Recent valuation commentary notes short‑term share volatility (mixed 1‑, 3‑month returns) — useful context for traders but not a direct fundamental change. Valuation and Volatility Analysis

Thermo Fisher Scientific Trading Up 2.5%

Shares of Thermo Fisher Scientific stock opened at $527.26 on Wednesday. The stock has a fifty day simple moving average of $503.14 and a 200 day simple moving average of $550.25. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $643.99. The company has a market capitalization of $195.94 billion, a P/E ratio of 29.72, a price-to-earnings-growth ratio of 2.75 and a beta of 0.97. The company has a current ratio of 1.89, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.45 by $0.12. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The business had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.95 billion. During the same quarter in the prior year, the company posted $6.10 earnings per share. Thermo Fisher Scientific’s revenue was up 7.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Investors of record on Friday, March 13th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.4%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. The ex-dividend date is Friday, March 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.60%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $541.20, for a total value of $216,480.00. Following the transaction, the executive vice president owned 20,752 shares of the company’s stock, valued at approximately $11,230,982.40. The trade was a 1.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 5,000 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $63,499,170. This represents a 3.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

TMO has been the subject of a number of research reports. Citigroup raised their price objective on Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Robert W. Baird set a $653.00 price objective on Thermo Fisher Scientific in a research note on Friday, January 30th. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Stifel Nicolaus raised their price objective on Thermo Fisher Scientific from $583.00 to $700.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Finally, Barclays reduced their price objective on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average price target of $631.25.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.